SANOFI SA INHABER EO 2/ FR0000120578 /
30/05/2024 22:59:44 | Chg. +0.270 | Volume | Bid22:59:44 | Ask22:59:44 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
88.140EUR | +0.31% | - Turnover: - |
88.140Bid Size: - | 88.280Ask Size: - | 111.03 bill.EUR | 4.25% | 20.55 |
GlobeNewswire
30/05
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...
GlobeNewswire
30/05
SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
GlobeNewswire
27/05
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
21/05
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
20/05
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
20/05
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
20/05
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
13/05
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
13/05
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
13/05
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
10/05
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
08/05
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
07/05
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights